Effectiveness of the Adjuvanted Recombinant Zoster Vaccine in Adults ≥50 Years in the United States

  • Tseng H
  • Sy L
  • Ackerson B
  • et al.
4Citations
Citations of this article
10Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: Recombinant zoster vaccine (RZV) was approved for adults aged ≥50 years in the United States to prevent herpes zoster (HZ) and postherpetic neuralgia (PHN). This study evaluated real-world vaccine effectiveness (VE) of RZV in adults aged ≥50 years. Methods: A cohort study was conducted at Kaiser Permanente Southern California (KPSC). The exposed cohort included members aged ≥50 years who received 1 or 2 RZV doses 04/2018-12/2020. They were matched 1:4 with unvaccinated individuals by age, sex, and race/ethnicity, then followed until 12/2022. Adjusted VE (aVE) and 95% confidence interval (CI) were estimated via stratified Cox models for 1 dose and 2 doses against HZ (diagnostic codes B02.xx plus antiviral within 7 days) and PHN (chart review for HZ-related pain persisting >3 months). Stratified aVE 2 by demographic characteristics, immunocompromised status, comorbidities, concomitant vaccination, and overall durability were assessed. Results: Among N=102,766 (median age 68 years) who received 2 RZV doses (4 weeks-6 months apart), 48,028 (46.7%) had previously received zoster vaccine live; aVE was 73.9% (95% CI:71.8%-75.8%) for HZ and 83.7% (95% CI:75.1%-89.3%) for PHN. VE against HZ was comparable across individuals with concomitant vaccinations and different comorbidities. VE against HZ and PHN remained stable over 4 years post-vaccination. One-dose VE was 60.3% (56.4%-63.9%) against HZ and 45.6% (11.4%-66.6%) against PHN. Conclusions: Two doses of RZV were effective in preventing HZ and PHN in adults aged ≥50 years, with durable protection. These findings underscore the importance of adhering to the recommended vaccination schedule. Key points: Among adults ≥50 years, 2 doses of recombinant zoster vaccine were highly effective against shingles and postherpetic neuralgia, an effect which remained stable for 4 years after vaccination. Vaccine effectiveness against shingles was comparable in people with different medical conditions.

Cite

CITATION STYLE

APA

Tseng, H.-F., Sy, L. S., Ackerson, B. K., Rayens, E., Wu, J., Luo, Y., … Qian, L. (2025). Effectiveness of the Adjuvanted Recombinant Zoster Vaccine in Adults ≥50 Years in the United States. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaf329

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free